Genascence Granted FDA Fast Track Designation for GNSC-001 in …
2 days ago · News provided by Genascence Nov 12, 2024, 07:45 ET. Share this article. Share to X. Share this article. Share to X. GNSC-001 is first gene therapy for prevalent musculoskeletal diseases like OA ...
Genascence Granted FDA Fast Track Designation for GNSC-001 in …
2 days ago · GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint; IL-1 is a key mediator involved in pathogenesis of OA OA affects more ...
News & Publications - Genascence
May 17, 2022 · Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting.
Gene Therapy for Osteoarthritis Gets Fast Track Status
2 days ago · The Food and Drug Administration (FDA) has granted Fast Track designation to GNSC-001 for the treatment of osteoarthritis of the knee. GNSC-001 is an investigational, adeno-associated virus gene ...
Genascence Announces Completion of Dosing and Interim Safety …
May 5, 2022 · Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis. May 5, 2022 | Press Release. Read More. Revolutionizing treatment for musculoskeletal diseases.
Press Release Archives - Genascence
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress. by Rachel Black | Oct 24, 2023 | Press Release.
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 …
Jan 3, 2024 · The DONATELLO Phase 1b clinical trial (NCT05835895) is a randomized, double-blinded, placebo-controlled dose ranging study designed to evaluate the safety, tolerability, and pharmacodynamics of a single intra-articular injection of GNSC …
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 …
Jan 3, 2024 · Genascence Corporation today announced the initiation of its Phase 1b clinical trial of GNSC-001 for the treatment of knee osteoarthritis (OA) (DONATELLO). Phase 1b clinical trial in the U.S. is actively recruiting patients with OA at …
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 …
Jan 3, 2024 · GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks interleukin-1 (IL-1) signaling.
Genascence Initiates Knee Osteoarthritis Gene Therapy Trial
Jan 26, 2024 · GNSC-001 uses a recombinant AAV vector to deliver an optimized form of IL-1Ra designed to block interleukin-1 (IL-1) signaling, which contributes to inflammation, joint pain, and cartilage destruction in knee OA.